Moberg Pharma interim report January – June 2013

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 6, 2013 at 2:15 AM

CONTINUED GROWTH AND INCREASED FINANCIAL STRENGTH PREPARING FOR PORTFOLIO EXPANSION FIRST SIX MONTH (JAN-JUN 2013) · Revenue MSEK 83.4 (55.5) · EBITDA MSEK -7.3 (9.4), loss of MSEK 4.2 excluding acquisition-related costs · Operating loss (EBIT) MSEK 10.3 (profit: 9.3) · Net loss after tax MSEK 7.0 (profit: 39.4) · Loss per share SEK 0.65 (earnings: 4.33) · Operating cash flow per share negative SEK 0.09 (pos: 0.64) SECOND QUARTER (APR-JUN 2013) · Revenue MSEK 44.9 (24.5) · EBITDA MSEK -5.1 (1.4), loss of MSEK 5.1 excluding acquisition-related costs · Operating loss (EBIT) MSEK 6.6 (profit: 1.4) · Net loss after tax MSEK 4.3 (profit: 1.4) · Loss per share SEK 0.39 (earnings: 0.15) · Operating cash flow per share negative SEK 0.06 (pos: 1.71) SIGNIFICANT EVENTS DURING THE SECOND QUARTER · The company changed its corporate identity to Moberg Pharma · Moberg Pharma and Paladin expanded their distribution agreement for Kerasal Nail™ to Mexico · Patient enrollment completed in clinical study of MOB-015 SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER · Financing of portfolio expansion secured through a private placement of MSEK 36 to Bure Equity · Distribution agreement with Menarini for Kerasal Nail expanded to China CEO COMMENTARY Moberg Pharma is continuing to grow at a rapid pace. Product sales in the second quarter of the year rose 107 percent compared with the year-earlier period. In the U.S., sales performed better than expected and, for the first time, our proprietary sales accounted for the majority of revenue. Kerasal® Nail™ is now the best-selling product in its segment in the U.S with a market share of 19% increasing from 10% in the same period last year . The trend in Europe to date this year has been weaker than expected. We are achieving major successes in such key markets as France, Italy and the Netherlands, although overall growth in Europe is affected by intensifying competition. Increased share of proprietary sales improved our gross margin from 69% to 78% during the first six months. Increased distribution of our current products In the U.S., additional retailers, including national mass retailer Target, and regional retailers such as Meijer and Hannaford, have added our products to their shelves. Kerasal® Nail™ is now available at approximately 30 000 retail outlets in the U.S. With increased distribution and strong demand for Kerasal® Nail™, we have increased our marketing investments, which normally peak during the second quarter. We also continue to expand our network of distributors in other parts of the world. In recent months, we signed new distribution agreements for two important and emerging markets – China and Mexico – with our existing partners Menarini Asia-Pacific and Paladin Labs, respectively. The Chinese market for non-prescription products is growing rapidly and presents significant growth opportunities, but naturally also substantial challenges. Preparations for market approval in China have been initiated. Pipeline progress The ongoing clinical study of MOB-015, our drug candidate for the treatment of nail fungus, is continuing according to plan. Patient enrollment for the study was completed during the quarter. To strengthen our pipeline, we are continuously evaluating acquisition and in-licensing opportunities, focusing on OTC brands for the U.S. markets, but also on development projects and technologies. Strengthened financing and resources for growth In early July we strengthened our financial position through a private placement to Bure Equity, which enhances our freedom of scope for continued growth. Our organic sales growth will make us profitable, although individual quarters may result in losses, due to timing of marketing investments and large orders from customers and distributors. We are making significant growth investments – in our brands with marketing investments, mainly in Kerasal® Nail™ – but also in the planned expansion of the product portfolio with acquisitions and proprietary development projects. We retain our expectation of achieving profitability on a full-year basis and an EBITDA margin of 25 percent within two to four years. Strong demand for our products, a larger geographical reach driven by new and expanded distribution agreements, and a strengthened financial position provide excellent conditions for continuing to build a different kind of pharmaceutical company. We are now ready to fuel our growth by adding brands, products and projects to our portfolio through acquisitions and in-licensing. Peter Wolpert, CEO Moberg Pharma TELEPHONE CONFERENCE CEO Peter Wolpert will present the report in a telephone conference today at 10:30 a.m. (CET), August 6th, 2013. Telephone: +46 (0)8-506 26 900 and submit the code 409017 ABOUT THIS INFORMATION Moberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 am (CET) on August 6th, 2013. FOR FURTHER INFORMATION, PLEASE CONTACT: Peter Wolpert, President and CEO of Moberg Pharma Mobile: +46 70-735 71 35 E -mail: peter.wolpert@mobergpharma.se Magnus Persson, IR Mobile: +46 73-355 26 01 E-mail: magnus.persson@mobergpharma.se For further information about Moberg Pharma, please visit: www.mobergpharma.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....